What's in Chinese Academy of Medical Sciences's pipeline?

Chinese Academy of Medical Sciences has 25 drugs in our index: 7 marketed, 0 filed, 15 in Phase 3, 1 in Phase 2, 2 in Phase 1.

Which companies overlap with Chinese Academy of Medical Sciences's portfolio?

Top competitors by shared drug class: Merck Sharp & Dohme LLC, Sanofi, GlaxoSmithKline, Jiangsu HengRui Medicine Co., Ltd., Bandim Health Project.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/chinese-academy-of-medical-sciences.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-17 · How we verify

Chinese Academy of Medical Sciences — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Chinese Academy of Medical Sciences pipeline: 7 marketed, 0 filed, 15 Phase 3, 1 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

7 marketed 0 filed 15 Phase 3 1 Phase 2 2 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
singular	singular	marketed			Other
OM-85 BV	OM-85 BV	marketed	Bacterial lysate immunostimulant		Immunology / Infectious Disease
live attenuated Japanese encephalitis vaccine	live attenuated Japanese encephalitis vaccine	marketed	Live attenuated vaccine		Immunology
pemetrexed plus cisplatin	pemetrexed plus cisplatin	marketed
two measles attenuated live vaccine	two measles attenuated live vaccine	marketed
Idarubicin(IDA)	Idarubicin(IDA)	marketed	Anthracycline topoisomerase II inhibitor	Topoisomerase II; DNA	Oncology
MSC+ATG	MSC+ATG	marketed			Other
Platinum-Based Drug	Platinum-Based Drug	phase 3	Platinum-based chemotherapy agent	DNA	Oncology
bOPV(Liquid)	bOPV(Liquid)	phase 3	vaccine		Infectious Diseases
bOPV(Candy)	bOPV(Candy)	phase 3			Infectious Diseases
Epirubicin, CTX, Paclitaxel	Epirubicin, CTX, Paclitaxel	phase 3	Combination chemotherapy (anthracycline + taxane + alkylating agent)	Topoisomerase II (epirubicin), β-tubulin/microtubules (paclitaxel), DNA alkylation (cyclophosphamide)	Oncology
oxaliplatin;s1	oxaliplatin;s1	phase 3	Platinum-based chemotherapy	DNA	Oncology

Therapeutic area mix

Oncology · 14
Infectious Diseases · 2
Other · 2
Immunology · 1
Immunology / Infectious Disease · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Merck Sharp & Dohme LLC · 5 shared drug classes
Sanofi · 4 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Jiangsu HengRui Medicine Co., Ltd. · 3 shared drug classes
Bandim Health Project · 2 shared drug classes
Beijing Center for Disease Control and Prevention · 2 shared drug classes
Canadian Immunization Research Network · 2 shared drug classes
Aga Khan University · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Chinese Academy of Medical Sciences:

Cite this brief

Drug Landscape (2026). Chinese Academy of Medical Sciences — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/chinese-academy-of-medical-sciences. Accessed 2026-05-17.